Exelixis, Inc. (EXEL) is trading at $43.77, up 8.41 percent, or $3.40 on Monday, after the company announced positive topline results from its Phase 3 STELLAR-303 trial in metastatic colorectal cancer.
The stock opened at $49.36 and has traded between $43.03 and $49.40 so far today. Volume has surged to 6.82 million shares, well above the average of 2.97 million. Exelixis shares have ranged between $21.82 and $49.40 over the past 52 weeks.
The study showed that its investigational drug Zanzalintinib, combined with Genentech's Tecentriq, significantly improved overall survival compared to Bayer's Regorafenib in previously treated patients.
)
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.